Ann: Results of BNC210 Agitation Trial, page-67

I will say this for Errol for a biotech ceo that needed to have the difference between clinical and pre-clinical explained to him he really has perfected picking the absolute worst times to dilute shareholders.

Normally CEOs would act in the interest of existing holders and lipstick up the pig first. Not old snoozy he has perfected doing nothing at all, dropping the pig out of the tree, sending it to the slaughter house then asking for more money to feed it.